403 related articles for article (PubMed ID: 22761470)
21. Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.
Ismail A; Bandla S; Reveiller M; Toia L; Zhou Z; Gooding WE; Kalatskaya I; Stein L; D'Souza M; Litle VR; Peters JH; Pennathur A; Luketich JD; Godfrey TE
Clin Cancer Res; 2011 Jul; 17(13):4513-22. PubMed ID: 21593195
[TBL] [Abstract][Full Text] [Related]
22. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
23. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
24. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ
PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593
[TBL] [Abstract][Full Text] [Related]
25. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
Semczuk A; Miturski R; Skomra D; Jakowicki JA
Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
[TBL] [Abstract][Full Text] [Related]
26. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.
Liu F; Korc M
Mol Cancer Ther; 2012 Oct; 11(10):2138-48. PubMed ID: 22869556
[TBL] [Abstract][Full Text] [Related]
27. The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.
Cabrera MC; Díaz-Cruz ES; Kallakury BV; Pishvaian MJ; Grubbs CJ; Muccio DD; Furth PA
Cancer Prev Res (Phila); 2012 Jun; 5(6):810-21. PubMed ID: 22508966
[TBL] [Abstract][Full Text] [Related]
28. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.
Casimiro MC; Velasco-Velázquez M; Aguirre-Alvarado C; Pestell RG
Expert Opin Investig Drugs; 2014 Mar; 23(3):295-304. PubMed ID: 24387133
[TBL] [Abstract][Full Text] [Related]
29. The CDK4/6 inhibitor PD0332991 stabilizes FBP1 by repressing MAGED1 expression in pancreatic ductal adenocarcinoma.
Zhang B; Li D; Jin X; Zhang K
Int J Biochem Cell Biol; 2020 Nov; 128():105859. PubMed ID: 32987196
[TBL] [Abstract][Full Text] [Related]
30. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
[TBL] [Abstract][Full Text] [Related]
31. Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.
Huang L; Lang D; Geradts J; Obara T; Klein-Szanto AJ; Lynch HT; Ruggeri BA
Mol Carcinog; 1996 Feb; 15(2):85-95. PubMed ID: 8599583
[TBL] [Abstract][Full Text] [Related]
32. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
[TBL] [Abstract][Full Text] [Related]
33. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
34. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.
Easton J; Wei T; Lahti JM; Kidd VJ
Cancer Res; 1998 Jun; 58(12):2624-32. PubMed ID: 9635589
[TBL] [Abstract][Full Text] [Related]
35. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
[TBL] [Abstract][Full Text] [Related]
36. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
[TBL] [Abstract][Full Text] [Related]
37. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
38. Gankyrin promotes the proliferation of human pancreatic cancer.
Meng Y; He L; Guo X; Tang S; Zhao X; Du R; Jin J; Bi Q; Li H; Nie Y; Liu J; Fan D
Cancer Lett; 2010 Nov; 297(1):9-17. PubMed ID: 20483533
[TBL] [Abstract][Full Text] [Related]
39. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Saab R; Bills JL; Miceli AP; Anderson CM; Khoury JD; Fry DW; Navid F; Houghton PJ; Skapek SX
Mol Cancer Ther; 2006 May; 5(5):1299-308. PubMed ID: 16731763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
